Multi-Tissue Proteomic Profiling for Alzheimer's Disease Biomarker Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring Alzheimer's disease (AD) are limited by their reliance on single-tissue analyses and lack of genetic specificity, which hampers the identification of reliable biomarkers and understanding of the disease's heterogeneous nature.
Innovation Solution
Multi-tissue proteomic profiling of brain, cerebrospinal fluid (CSF), and plasma samples to identify molecular signatures associated with sporadic AD, TREM2 risk variant carriers, and autosomal dominant AD, creating tissue-specific prediction models that outperform existing biomarkers like CSF Aβ/tau ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If single-tissue analysis is used for AD diagnosis, then the diagnostic method is simple and easy to implement, but the identification of reliable biomarkers is limited and the understanding of disease heterogeneity is insufficient
Solution Approach 1:
The patent divides the analysis into multiple independent tissue compartments (brain, CSF, plasma) and identifies tissue-specific protein signatures for different AD subtypes. Each tissue is analyzed separately to capture unique biomarker profiles, then integrated to provide comprehensive diagnostic information. This segmentation allows identification of reliable tissue-specific biomarkers that would be missed in pooled analysis.
Solution Approach 2:
The patent transitions from single-tissue analysis to multi-tissue dimensional analysis, adding the tissue-of-origin dimension to the biomarker identification process. By analyzing proteins across multiple tissue compartments simultaneously, the method captures the heterogeneous nature of AD pathology in different biological spaces, improving biomarker identification precision without sacrificing clinical feasibility.
2Measurement precision
If multi-tissue proteomic profiling is performed to identify molecular signatures, then the diagnostic precision and disease understanding are improved, but the complexity of the analysis method increases
Solution Approach 1:
The patent employs a universal proteomic analysis framework that can be applied across multiple tissue types using the same analytical pipeline. The multi-tissue proteomic profiling approach uses consistent protein quantification methods and statistical analysis procedures adapted for each tissue, providing a unified multi-functional platform that improves diagnostic precision while managing complexity through standardization.
Solution Approach 2:
The patent applies tissue-specific analysis parameters and interpretation criteria tailored to each tissue type's unique characteristics. Each tissue (brain, CSF, plasma) is analyzed with appropriate local quality controls and reference ranges, allowing the method to capture tissue-specific pathological signatures while maintaining overall analytical consistency through standardized protocols.
3Reliability
If tissue-specific prediction models are created for different AD subtypes, then the genetic specificity and diagnostic accuracy are improved, but the number of required samples and analysis time increase
Solution Approach 1:
The patent performs preliminary clustering analysis to identify distinct AD subtypes (sporadic AD, TREM2 variant carriers, autosomal dominant AD) from multi-tissue proteomic data before creating prediction models. This preliminary classification groups samples by molecular signature, allowing subsequent analysis to focus on subtype-specific patterns and reducing the computational burden of analyzing all samples uniformly, thereby improving genetic specificity while managing analysis time.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of detecting proteins associated with Alzheimer's disease (AD) or risk variant thereof; diagnosis, prognosis, and monitoring of disease progression; or monitoring treatment.